Bilski: Assessing the Impact of a Newly Invigorated Patent-Eligibility Doctrine on the Pharmaceutical Industry and the Future of Personalized Medicine

Publisher： Bentham Science Publishers

E-ISSN： 1873-4294|10|18|1937-1949

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.10, Iss.18, 2010-12, pp. : 1937-1949

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 6, Iss. 2, 2008-06 ,pp. : 108-120

Bentham Science Publishers

Access to resources Recommend Favorite

The Community Patent: What This Means for the Pharmaceutical Industry

By Cohen L.J.  

Pharmaceutical Development and Regulation, Vol. 1, Iss. 1, 2003-01 ,pp. : 3-10

Adis International

Access to resources Recommend Favorite

The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine

By  

Current Drug Metabolism, Vol. 12, Iss. 5, 2011-06 ,pp. : 460-486

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine

By Vizirianakis I.S.  

European Journal of Pharmaceutical Sciences, Vol. 15, Iss. 3, 2002-04 ,pp. : 243-250

Elsevier

Access to resources Recommend Favorite

Reforming Pharmaceutical Education to Enhance the Global Uptake of Pharmacogenomics and Personalized Medicine

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 10, Iss. 3, 2012-09 ,pp. : 231-238

Bentham Science Publishers

Access to resources Recommend Favorite